Carcinoid syndrome laboratory tests: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
*Testing for elevated urinary [[5-hydroxyindoleacetic acid]] (5-HIAA) has a specificity of approximately 88%, although the sensitivity is reported to be as low as 35%.
*Testing for elevated urinary [[5-hydroxyindoleacetic acid]] (5-HIAA) has a specificity of approximately 88%, although the sensitivity is reported to be as low as 35%.
*Plasma levels of Chromogranin A (CgA) are very sensitive markers of carcinoid syndrome, but not specific as they are also elevated in other types of neuroendocrinal tumors such as [[pancreatic]] and [[lung carcinoma|small cell lung carcinomas]].
*Plasma levels of Chromogranin A (CgA) are very sensitive markers of carcinoid syndrome, but not specific as they are also elevated in other types of neuroendocrinal tumors such as [[pancreatic]] and [[lung carcinoma|small cell lung carcinomas]].
*NT-proBNP is a useful biomarker of carcinoid heart disease at a cutoff level of 260 pg/ml (31 pmol/l) and has been used as a screening tool for carcinoid heart disease in patients with carcinoid syndrome
*N-terminal pro–B-type natriuretic peptide :NT-proBNP is a useful biomarker of carcinoid heart disease at a cutoff level of 260 pg/ml (31 pmol/l)
*N-terminal pro–B-type natriuretic peptide used as a screening tool for carcinoid heart disease in patients with carcinoid syndrome.
*Other biochemical markers associated with carcinoid syndrome include:<ref name="diagnostics">Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
*Other biochemical markers associated with carcinoid syndrome include:<ref name="diagnostics">Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
**[[Substance P]]
**[[Substance P]]

Revision as of 23:33, 4 January 2019

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome laboratory tests

CDC on Carcinoid syndrome laboratory tests

Carcinoid syndrome laboratory tests in the news

Blogs on Carcinoid syndrome laboratory tests

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Laboratory findings consistent with the diagnosis of carcinoid syndrome include an elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) and plasma levels of Chromogranin A (CgA) levels.

Laboratory Findings

  • Urinary 5-hydroxyindoleacetic acid (5-HIAA) are elevated and plasma levels of Chromogranin A (CgA) levels.[1]
  • Testing for elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) has a specificity of approximately 88%, although the sensitivity is reported to be as low as 35%.
  • Plasma levels of Chromogranin A (CgA) are very sensitive markers of carcinoid syndrome, but not specific as they are also elevated in other types of neuroendocrinal tumors such as pancreatic and small cell lung carcinomas.
  • N-terminal pro–B-type natriuretic peptide :NT-proBNP is a useful biomarker of carcinoid heart disease at a cutoff level of 260 pg/ml (31 pmol/l)
  • N-terminal pro–B-type natriuretic peptide used as a screening tool for carcinoid heart disease in patients with carcinoid syndrome.
  • Other biochemical markers associated with carcinoid syndrome include:[1]

References

  1. 1.0 1.1 Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq

Template:WS Template:WH